<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775004</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20-1394</org_study_id>
    <nct_id>NCT04775004</nct_id>
  </id_info>
  <brief_title>Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)</brief_title>
  <official_title>Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Orthopaedic Society for Sports Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no current or past RCT comparing biologic augments for meniscal repair. There is&#xD;
      good data supporting both the use of BMVP of the intercondylar notch and intra-articular PRP&#xD;
      injections for augmentation of meniscal repair. However, the effectiveness of these&#xD;
      augmentation methods with respect to each other has never been investigated. The knowledge&#xD;
      gained will allow us to potentially influence and adapt protocols to treat this particular&#xD;
      patient population. Additionally, resources available at our institution provide a supportive&#xD;
      framework with which to maintain contact with patients after hospital discharge. These key&#xD;
      factors will allow us to perform a robust analysis of this population, to include outcomes&#xD;
      measures of function as well as meniscal repair failure and reoperation rate.&#xD;
&#xD;
      The proposed interventional aim to compare meniscal repair augmentation methods is novel, as&#xD;
      the direct comparison of these outcome measures has not been previously described. Because of&#xD;
      the known benefit of biologic augmentation of meniscal repair, the investigators hypothesize&#xD;
      that the repair failure rate for both cohorts will be lower than the reported repair failure&#xD;
      rate for isolated tears without biologic augmentation; the investigators also hypothesize&#xD;
      that BMVP of the intercondylar notch will clinically be significantly better than&#xD;
      intra-articular PRP injection. The basis behind this hypothesis is in vivo evidence as well&#xD;
      as a small RCT supporting the use of BMVP as augmentation for meniscal repair procedures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Promis Physical function CAT lower extremity score</measure>
    <time_frame>1-year after meniscus tear operation.</time_frame>
    <description>Adaptive questionnaire that takes five minutes or less to complete and helps record how subject injury and recovery from surgery is affecting their normal life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Re-tear of repair meniscus</measure>
    <time_frame>1-year after meniscus tear operation.</time_frame>
    <description>Clinically reported (symptomatic) and MRI confirmed via observation of fluid filled tear in the repaired tissue</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Meniscal Tear</condition>
  <arm_group>
    <arm_group_label>Bone marrow venting procedure (BMVP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized in the OR to undergo BMVP surgical augmentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet rich plasma (PRP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized in the OR to undergo PRP surgical augmentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone marrow venting procedure (BMVP)</intervention_name>
    <description>The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.</description>
    <arm_group_label>Bone marrow venting procedure (BMVP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Platelet Rich Plasma (PRP)</intervention_name>
    <description>The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.</description>
    <arm_group_label>Platelet rich plasma (PRP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age 16 or older&#xD;
&#xD;
          2. Medial, lateral, vertical longitudinal, oblique, or radial meniscal tear&#xD;
&#xD;
          3. Complex tears may be included at the discretion of the site investigator if patient&#xD;
             has one of tear patterns listed in inclusion criteria 2 as the most predominant&#xD;
             finding&#xD;
&#xD;
          4. No other concomitant procedure unless one of the following:&#xD;
&#xD;
               -  Chondroplasty&#xD;
&#xD;
               -  Synovectomy&#xD;
&#xD;
               -  Loose body removal&#xD;
&#xD;
               -  &quot;Contralateral&quot; menisectomy (i.e. medial meniscus repair with a lateral&#xD;
                  menisectomy or lateral meniscus repair with a medial menisectomy) would be&#xD;
                  permitted for inclusion&#xD;
&#xD;
               -  Any other procedure that does not include drilling, requires prior approval of&#xD;
                  the study sponsor for each procedure&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients requiring cartilage restorative or repair procedures (i.e. OCD fixation,&#xD;
             micro-fracture repair, or others)&#xD;
&#xD;
          2. Patients with meniscus root tears&#xD;
&#xD;
          3. Patients undergoing repair for horizontal cleavage tears&#xD;
&#xD;
          4. Kellgren-Lawrence scale 3&gt;&#xD;
&#xD;
          5. Patients undergoing lateral release&#xD;
&#xD;
          6. Ipsilateral chondral lesion with Outerbridge classification of 3-4&#xD;
&#xD;
          7. Use of prednisone or other steroids, any immunosuppressant, or chemotherapy 1-week&#xD;
             before surgery or expected use within six weeks after surgery&#xD;
&#xD;
          8. Cortisone use within the six weeks prior to surgery&#xD;
&#xD;
          9. Utilizing worker's compensation at the time of screening&#xD;
&#xD;
         10. Any previous ligament surgery on the index limb. Any previous meniscal surgery on the&#xD;
             index meniscus.&#xD;
&#xD;
         11. Concomitant ligamentous insufficiency&#xD;
&#xD;
         12. Inflammatory rheumatic disease or other rheumatic disease&#xD;
&#xD;
         13. Immune compromised patients (hepatitis, HIV, etc.)&#xD;
&#xD;
         14. Any nicotine based products within the three months prior to surgery (including&#xD;
             cigarettes, cigars, vaping, nicotaine patch, etc)&#xD;
&#xD;
         15. History of distal femur, proximal tibia, or patellar fracture that was treated&#xD;
             operatively&#xD;
&#xD;
         16. Non English-speaking patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aravind Athiviraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Bell</last_name>
    <phone>773-834-0822</phone>
    <email>jbell3@bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Bell</last_name>
      <phone>773-834-0822</phone>
    </contact>
    <investigator>
      <last_name>Aravind Athiviraham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

